Atai Life Sciences N.V.

NasdaqGM:ATAI

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

🧠 Mental Health

💊 Pharmaceuticals

Location

Germany

Market Cap

USD 444.67 M

Share Price

USD 2.11

Avg Daily Volume

1,975,701

Change (1 day)

-3.21%

Change (1 year)

57.46%

Change (YTD)

58.65%

Atai Life Sciences N.V. Price to Earnings Ratio (P/E) on June 13, 2025

Atai Life Sciences N.V. Price to Earnings Ratio (P/E) is NA on June 13, 2025. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Atai Life Sciences N.V. 52-week low Price to Earnings Ratio (P/E) is -1.38 on June 13, 2025, which is NA below the current Price to Earnings Ratio (P/E).
Atai Life Sciences N.V. 52-week low Price to Earnings Ratio (P/E) is -6.87 on June 13, 2025, which is NA below the current Price to Earnings Ratio (P/E).
Atai Life Sciences N.V. average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.03.

Daily

From:

To:

Zoom:

Key data

Date	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)	Enterprise Value to EBITDA (EV/EBITDA)

NasdaqGM: ATAI

Atai Life Sciences N.V.

CEO	Dr. Srinivas G. Rao M.D., Ph.D.
IPO Date	June 18, 2021
Location	Germany
Headquarters	Krausenstrasse 9-10
Employees	54
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 🧠 Mental Health 💊 Pharmaceuticals

Description

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.